Abbott Full-Year Report 2022

• Fourth-quarter sales of $10.1 billion, which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of foreign exchange.
• Excluding COVID-19 testing-related sales1 , fourth-quarter sales decreased 1.4 percent on a reported
basis and increased 5.4 percent on an organic basis.
• Excluding COVID-19 testing-related sales and U.S. infant formula sales that were impacted by manufacturing disruptions, full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
• GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03.

Worldwide COVID-19 testing-related sales were $1.069 billion in the fourth quarter of 2022
compared to $2.319 billion in the fourth quarter of the prior year. Worldwide COVID-19 testingrelated sales were $8.368 billion in the full year of 2022 compared to $7.679 billion in the prior year